Molecular determinants of antagonist interactions with chemokine receptors CCR2 and CCR5.

ABSTRACT: By driving monocyte chemotaxis, the chemokine receptor CCR2 shapes inflammatory responses and the formation of tumor microenvironments. This makes it a promising target in inflammation and immuno-oncology; however, despite extensive efforts, there are no FDA-approved CCR2-targeting therapeutics. Cited challenges include the redundancy of the chemokine system, suboptimal properties of compound candidates, and species differences that confound the translation of results from animals to humans. Structure-based drug design can rationalize and accelerate the discovery and optimization of CCR2 antagonists to address these challenges. The prerequisites for such efforts include an atomic-level understanding of the molecular determinants of action of existing antagonists. In this study, using molec

SUBMITTER: Dawson JRD 

PROVIDER: S-EPMC10680698 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature